Compounds for the treatment of neurodegenerative diseases
View Patent ↗Compounds and their pharmaceutically acceptable salts for treatment of synucleinopathies, such as Parkinson's disease and tauopathies.
1. A compound selected from the group consisting of:
and
2. A composition comprising the compound of claim 1 and at least one pharmaceutically acceptable excipient.
3. An article of manufacture, comprising packaging material, the compound of claim 1 , or a pharmaceutically acceptable salt thereof, contained within packaging material, which is used for treating the formation, deposition, accumulation, or persistence of α-synuclein fibrils and/or aggregates, and a label that indicates that the compound or pharmaceutically acceptable salt thereof is used for treating the formation, deposition, accumulation, or persistence of α-synuclein fibrils and/or aggregates in a mammal suffering therefrom.
4. A method of disrupting or inhibiting the formation, deposition, accumulation, or persistence of synuclein fibrils and/or aggregates, comprising administering to a mammal having a synuclein disease a therapeutically effective amount of a compound selected from the group consisting of
and
5. The method of claim 4 , where the compound administered is in an amount between 0.1 mg/Kg/day and 1000 mg/Kg/day.
6. The method of claim 4 , where the compound is administered in an amount between 1 mg/Kg/day and 100 mg/Kg/day.
7. The method of claim 4 , where the compound is administered in an amount between 10 mg/Kg/day and 100 mg/Kg/day.
8. A method resulting in neuroprotection from a synuclein disease in a mammal suffering therefrom comprising the step of administrating a therapeutically effective amount of a compound selected from the group consisting of
and